AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1592715 — intervention group
Group type: COMPARATOR
Intervention: Placebo/Control (P/C)
Number of subjects: 30
Study 1592715 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo/Resistance Training (P/RT)
Number of subjects: 30
Study 1592715 — intervention group
Group type: EXPERIMENTAL
Intervention: Arginine/Lysine/Control (AL/C)
Number of subjects: 30
Study 1592715 — intervention group
Group type: EXPERIMENTAL
Intervention: Arginine/Lysine/Resistance Training (AL/RT)
Number of subjects: 30
Study 2867598 — intervention group
Group type: EXPERIMENTAL
Intervention: RP 40 749 (150 mg)
Number of subjects: 13
Study 2867598 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 31211638 — intervention group
Group type: EXPERIMENTAL
Intervention: HyFlex EDM NiTi rotary files
Number of subjects: 60
Study 31211638 — intervention group
Group type: COMPARATOR
Intervention: ProTaper Universal Retreatment NiTi Systems
Number of subjects: 60
Study 31211638 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser activated irrigation (PIPS)
Number of subjects: 60
Study 31211638 — intervention group
Group type: COMPARATOR
Intervention: Conventional needle irrigation
Number of subjects: 60
Study 29636247 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-valent pneumococcal conjugate vaccine (PCV7)
Number of subjects: 237
Study 29636247 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 237
Study 26260216 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialist-led physical education (SPE) program (100 min/week of CP PE replaced by SPE)
Number of subjects: 727
Study 26260216 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialist-led physical education (SPE) program
Number of subjects: 727
Study 26260216 — intervention group
Group type: COMPARATOR
Intervention: Common practice physical education (CP)
Number of subjects: 727
Study 25405390 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG plus mitral-valve repair (combined procedure)
Number of subjects: 301
Study 25405390 — intervention group
Group type: COMPARATOR
Intervention: CABG alone
Number of subjects: 301
Study 22476239 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral classic TAP block with 30 mL ropivacaine 0.375%
Number of subjects: 8
Study 22476239 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual 15 mL injections at the upper intercostal and lateral classic TAP plexuses
Number of subjects: 8
Study 22476239 — intervention group
Group type: EXPERIMENTAL
Intervention: All injectate areas
Number of subjects: 8
Study 22476239 — intervention group
Group type: EXPERIMENTAL
Intervention: Measured serum ropivacaine concentrations
Number of subjects: 8
Study 20573492 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiwei (6 g, twice daily for three days)
Number of subjects: 480
Study 20573492 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 480
Study 17785708 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised aerobic exercise
Number of subjects: 242
Study 17785708 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised resistance exercise
Number of subjects: 242
Study 17785708 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 242
Study 15117415 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 0
Study 15117415 — intervention group
Group type: COMPARATOR
Intervention: Dihydrocodeine
Number of subjects: 0
Study 11476307 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime-impregnated cement
Number of subjects: 78
Study 11476307 — intervention group
Group type: COMPARATOR
Intervention: Cement without cefuroxime
Number of subjects: 78
Study 9526912 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided tissue regeneration (GTR) procedure using a bioabsorbable membrane
Number of subjects: 54
Study 9526912 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided tissue regeneration (GTR) procedure using a non-resorbable membrane
Number of subjects: 54
Study 9526912 — intervention group
Group type: EXPERIMENTAL
Intervention: Mucogingival surgical approach with connective tissue graft and coronally advanced flap (bilaminar technique)
Number of subjects: 54
Study 9526912 — intervention group
Group type: COMPARATOR
Intervention: Comparison between bilaminar and non-resorbable membrane groups
Number of subjects: 54
Study 9526912 — intervention group
Group type: COMPARATOR
Intervention: All treatment approaches
Number of subjects: 54
Study 9526912 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 54
Study 8017507 — intervention group
Group type: EXPERIMENTAL
Intervention: Static orthosis at night (experimental group)
Number of subjects: 13
Study 8017507 — intervention group
Group type: COMPARATOR
Intervention: No static orthosis (control group)
Number of subjects: 13
Study 2728825 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN) 80 micrograms/kg
Number of subjects: 30
Study 2728825 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN) 40 micrograms/kg
Number of subjects: 30
Study 2728825 — intervention group
Group type: COMPARATOR
Intervention: Control (no ISDN)
Number of subjects: 30
Study 2728825 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (ISDN 40, ISDN 80, Control)
Number of subjects: 30
Study 787443 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine-HC1
Number of subjects: 153
Study 31109232 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast-track surgery (FTS)
Number of subjects: 80
Study 31109232 — intervention group
Group type: COMPARATOR
Intervention: Traditional treatments (Control)
Number of subjects: 80
Study 27402346 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation strategy consisting of a working group meeting, supervisor training in PA application, and optional supervisor coaching.
Number of subjects: 116
Study 27402346 — intervention group
Group type: COMPARATOR
Intervention: Written information on PA.
Number of subjects: 116
Study 25312348 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (intense exercise before or after encoding)
Number of subjects: 0
Study 25312348 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (intense exercise)
Number of subjects: 0
Study 23116369 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reward condition
Number of subjects: 100
Study 23116369 — intervention group
Group type: COMPARATOR
Intervention: Other-reward condition
Number of subjects: 100
Study 21651447 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitavastatin calcium 1 mg/day
Number of subjects: 40
Study 21651447 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitavastatin calcium 2 mg/day
Number of subjects: 40
Study 21651447 — intervention group
Group type: COMPARATOR
Intervention: Control (healthy subjects)
Number of subjects: 40
Study 19657829 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual-focused frame
Number of subjects: 0
Study 19657829 — intervention group
Group type: EXPERIMENTAL
Intervention: Collective-focused frame
Number of subjects: 0
Study 19657829 — intervention group
Group type: EXPERIMENTAL
Intervention: Joint frame
Number of subjects: 0
Study 19657829 — intervention group
Group type: COMPARATOR
Intervention: No-frames control
Number of subjects: 0
Study 16096256 — intervention group
Group type: EXPERIMENTAL
Intervention: Trunk Impairment Scale (TIS) for stroke patients
Number of subjects: 80
Study 16096256 — intervention group
Group type: COMPARATOR
Intervention: Trunk Impairment Scale (TIS) for healthy individuals
Number of subjects: 80
Study 12406481 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobacco/alcohol use-prevention program
Number of subjects: 660
Study 12406481 — intervention group
Group type: COMPARATOR
Intervention: Attention-control condition (first aid/home safety)
Number of subjects: 660
Study 10559769 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous MF exposure (100 mu T(rms) 50 Hz for 30 minutes)
Number of subjects: 21
Study 10559769 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent MF exposure (100 mu T(rms) 50 Hz for 30 minutes, 15 s ON/OFF cycles)
Number of subjects: 21
Study 10559769 — intervention group
Group type: EXPERIMENTAL
Intervention: Real MF exposure (100 mu T(rms) 50 Hz for 30 minutes)
Number of subjects: 21
Study 10559769 — intervention group
Group type: COMPARATOR
Intervention: Sham exposure (control)
Number of subjects: 21
Study 7576669 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative hypothermia (approximately 2.5 degrees C hypothermic)
Number of subjects: 74
Study 7576669 — intervention group
Group type: COMPARATOR
Intervention: Normothermic patients
Number of subjects: 74
Study 2156277 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg/kg L-tryptophan administered intravenously over 20 min
Number of subjects: 25
Study 2156277 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 25
Study 2156277 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg/kg L-tryptophan
Number of subjects: 25
Study 378348 — intervention group
Group type: EXPERIMENTAL
Intervention: Oophorectomy + vincristine, prednisone, cyclophosphamide, methotrexate, 5‐fluorouracil (VPCMF)
Number of subjects: 157
Study 378348 — intervention group
Group type: EXPERIMENTAL
Intervention: Oophorectomy + cyclophosphamide
Number of subjects: 157
Study 378348 — intervention group
Group type: COMPARATOR
Intervention: Oophorectomy followed by an observation period (Phase 1), followed by VPCMF (Phase 2)
Number of subjects: 157
Study 31769161 — intervention group
Group type: EXPERIMENTAL
Intervention: Firehawk stent
Number of subjects: 1585
Study 31769161 — intervention group
Group type: COMPARATOR
Intervention: XIENCE stent
Number of subjects: 1585
Study 31842992 — intervention group
Group type: EXPERIMENTAL
Intervention: Inverted syringe technique
Number of subjects: 100
Study 31842992 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 100
Study 27427181 — intervention group
Group type: EXPERIMENTAL
Intervention: Praat acoustic analysis
Number of subjects: 182
Study 25836591 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic Compression (IC)
Number of subjects: 90
Study 25836591 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry needling + Ischemic Compression (IC)
Number of subjects: 90
Study 25836591 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 25836591 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 90
Study 23775877 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprepitant
Number of subjects: 16
Study 23775877 — intervention group
Group type: COMPARATOR
Intervention: Alcohol
Number of subjects: 16
Study 23775877 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 16
Study 23775877 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprepitant + Alcohol
Number of subjects: 16
Study 21762225 — intervention group
Group type: EXPERIMENTAL
Intervention: TPI ASM8 (4 mg b.i.d.)
Number of subjects: 14
Study 21762225 — intervention group
Group type: EXPERIMENTAL
Intervention: TPI ASM8 (8 mg o.d.)
Number of subjects: 14
Study 19817982 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 100 mg
Number of subjects: 0
Study 19817982 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 50 mg
Number of subjects: 0
Study 19817982 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17348884 — intervention group
Group type: EXPERIMENTAL
Intervention: Transmucosal implant placement (test group)
Number of subjects: 10
Study 14732421 — intervention group
Group type: EXPERIMENTAL
Intervention: Social reinforcement of aftercare group therapy attendance
Number of subjects: 40
Study 14732421 — intervention group
Group type: COMPARATOR
Intervention: Standard aftercare orientation
Number of subjects: 40
Study 11230791 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg
Number of subjects: 41
Study 11230791 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 9756584 — intervention group
Group type: EXPERIMENTAL
Intervention: rtPA treatment
Number of subjects: 615
Study 9756584 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 615
Study 8148045 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride and postural dietetic limits
Number of subjects: 55
Study 8148045 — intervention group
Group type: EXPERIMENTAL
Intervention: Domperidone and postural dietetic limits
Number of subjects: 55
Study 8148045 — intervention group
Group type: COMPARATOR
Intervention: Postural dietetic limits only
Number of subjects: 55
Study 8148045 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment (both interventions)
Number of subjects: 55
Study 3075625 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol 0.5% twice daily
Number of subjects: 22
Study 3075625 — intervention group
Group type: COMPARATOR
Intervention: Contralateral eyes (no treatment)
Number of subjects: 22
Study 31357206 — intervention group
Group type: EXPERIMENTAL
Intervention: Baclofen
Number of subjects: 12
Study 31357206 — intervention group
Group type: COMPARATOR
Intervention: l-DOPA
Number of subjects: 12
Study 31357206 — intervention group
Group type: COMPARATOR
Intervention: Dextromethorphan
Number of subjects: 12
Study 31357206 — intervention group
Group type: COMPARATOR
Intervention: Rivastigmine
Number of subjects: 12
Study 31357206 — intervention group
Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 12
Study 29417288 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial lubricant instilled prior to biopsy
Number of subjects: 384
Study 29417288 — intervention group
Group type: COMPARATOR
Intervention: Standard lubricant
Number of subjects: 384
Study 29417288 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 384
Study 27068870 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 UA/day
Number of subjects: 131
Study 27068870 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 UA/day
Number of subjects: 131
Study 27068870 — intervention group
Group type: EXPERIMENTAL
Intervention: 2000 UA/day
Number of subjects: 131
Study 27068870 — intervention group
Group type: EXPERIMENTAL
Intervention: 3000 UA/day
Number of subjects: 131
Study 27068870 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 131
Study 25056766 — intervention group
Group type: EXPERIMENTAL
Intervention: Tension-free vaginal tape (TVT) procedure
Number of subjects: 128
Study 25056766 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic mesh colposuspension (LCM)
Number of subjects: 128
Study 24163815 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (urethra preserved until the level of verumontanum)
Number of subjects: 329
Study 24163815 — intervention group
Group type: COMPARATOR
Intervention: Group A (standard radical prostatectomy)
Number of subjects: 329
Study 24163815 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B
Number of subjects: 329
Study 24163815 — intervention group
Group type: COMPARATOR
Intervention: Group A
Number of subjects: 329
Study 21079818 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (ATO) 40 mg/day
Number of subjects: 14
Study 21079818 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 18421891 — intervention group
Group type: EXPERIMENTAL
Intervention: Group program focused on intensive training in techniques for eliciting the relaxation response (P1; n = 60)
Number of subjects: 225
Study 18421891 — intervention group
Group type: COMPARATOR
Intervention: Group program focused on healthy eating and physical activity (P2; n = 61)
Number of subjects: 225
Study 18421891 — intervention group
Group type: COMPARATOR
Intervention: Self-guided, mail-delivered version of P2 (P3; n = 101)
Number of subjects: 225
Study 15848518 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed chimerism protocol with thymic transplantation of donor renal tissue, two donor-specific transfusions, low-intensity conditioning, and high-dose HSCT before renal transplantation.
Number of subjects: 66
Study 15848518 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving standard immunosuppression (CyA and prednisolone) plus mycophenolate mofetil/azathioprine.
Number of subjects: 66
Study 12209704 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextromethorphan 60 mg
Number of subjects: 75
Study 12209704 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextromethorphan 90 mg
Number of subjects: 75
Study 12209704 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 10340790 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA‐DR2
Number of subjects: 93
Study 10340790 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA‐DR4
Number of subjects: 93
Study 10340790 — intervention group
Group type: EXPERIMENTAL
Intervention: DR2‐positive and DR4‐negative genotypes
Number of subjects: 93
Study 10340790 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA‐DQB1*0302
Number of subjects: 93
Study 10340790 — intervention group
Group type: EXPERIMENTAL
Intervention: DRB1*1501-positive, DRB1*0405-negative, and DQB1*0302-negative genotypes
Number of subjects: 93
Study 8746886 — intervention group
Group type: EXPERIMENTAL
Intervention: New chemotherapy
Number of subjects: 0
Study 8746886 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 0
Study 1701714 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcortical P300-like activity
Number of subjects: 0
Study 1701714 — intervention group
Group type: COMPARATOR
Intervention: Visual stimulus presentation (digit 6 or 9)
Number of subjects: 0
Study 6119042 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal budesonide 400 microgram per day
Number of subjects: 0
Study 6119042 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal budesonide 200 microgram per day
Number of subjects: 0
Study 6119042 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6119042 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal budesonide (both dosages)
Number of subjects: 0
Study 31800000 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate antiretroviral therapy (ART)
Number of subjects: 4249
Study 31800000 — intervention group
Group type: COMPARATOR
Intervention: Deferred antiretroviral therapy (ART)
Number of subjects: 4249
Study 30239571 — intervention group
Group type: EXPERIMENTAL
Intervention: Mendelian randomization (MR)
Number of subjects: 0
Study 28400487 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid artery stenting (CAS)
Number of subjects: 184
Study 28400487 — intervention group
Group type: COMPARATOR
Intervention: Carotid endarterectomy (CEA)
Number of subjects: 184
Study 25822050 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual interviews
Number of subjects: 56
Study 25822050 — intervention group
Group type: EXPERIMENTAL
Intervention: Focus groups
Number of subjects: 56
Study 24165392 — intervention group
Group type: EXPERIMENTAL
Intervention: ADM-facilitated one-stage implant reconstruction
Number of subjects: 0
Study 24165392 — intervention group
Group type: COMPARATOR
Intervention: Two-stage tissue expander/implant (TE/I) reconstruction
Number of subjects: 0
Study 21385158 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 150 mg
Number of subjects: 150
Study 21385158 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 19690943 — intervention group
Group type: EXPERIMENTAL
Intervention: Fascia iliaca compartment block (FICB) prophylaxis
Number of subjects: 207
Study 19690943 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 207
Study 17005549 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin 1.5% eye drops twice daily for 2 days
Number of subjects: 670
Study 17005549 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin 1.5% eye drops twice daily for 3 days
Number of subjects: 670
Study 17005549 — intervention group
Group type: COMPARATOR
Intervention: Azithromycin single 20 mg/kg oral dose
Number of subjects: 670
Study 17005549 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (eye drops and oral)
Number of subjects: 670
Study 15089820 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous tyramine injections
Number of subjects: 12
Study 15089820 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 11564358 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehomecare intervention
Number of subjects: 0
Study 11001599 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholinesterase inhibitor therapy (donepezil)
Number of subjects: 30
Study 9104896 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin treatment at hospital admission
Number of subjects: 1286
Study 9104896 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium antagonists treatment at hospital admission
Number of subjects: 1286
Study 9104896 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta blockers treatment at hospital admission
Number of subjects: 1286
Study 9104896 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination anti-ischemic therapy at hospital admission
Number of subjects: 1286
Study 9104896 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrates treatment at discharge
Number of subjects: 1286
Study 9104896 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination anti-ischemic therapy at discharge
Number of subjects: 1286
Study 9104896 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitors treatment
Number of subjects: 1286
Study 9104896 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-lowering agents treatment
Number of subjects: 1286
Study 1487611 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal spleno-renal shunt (DSRS)
Number of subjects: 4
Study 1487611 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal spleno-renal shunt (DSRS) in non-alcoholic patients
Number of subjects: 4
Study 1487611 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic sclerotherapy (EVS)
Number of subjects: 4
Study 2881819 — intervention group
Group type: EXPERIMENTAL
Intervention: IPV + pertussis
Number of subjects: 4
Study 2881819 — intervention group
Group type: EXPERIMENTAL
Intervention: IPV + DP
Number of subjects: 4
Study 2881819 — intervention group
Group type: EXPERIMENTAL
Intervention: IPV + DTP
Number of subjects: 4
Study 2881819 — intervention group
Group type: COMPARATOR
Intervention: IPV alone
Number of subjects: 4
Study 29660351 — intervention group
Group type: EXPERIMENTAL
Intervention: Betrixaban
Number of subjects: 7513
Study 29660351 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care enoxaparin
Number of subjects: 7513
Study 29660351 — intervention group
Group type: EXPERIMENTAL
Intervention: Low hemoglobin (categorical or continuous)
Number of subjects: 7513